作为血透耗材领域国产替代的标杆企业，威高血净紧抓医疗器械产业高质量发展与国产替代加速的政策 机遇，实现了血透耗材市占率领先。"'十四五'时期的政策赋能为威高血净发展提供了关键支撑。"威高 血净介绍，在此时期，国家将血液净化关键技术列为重点攻关方向，设立专项研发资金，公司突破了中 空纤维膜等"卡脖子"技术，21年磨一剑完成"膜法革命"。与此同时，国家对医疗器械创新产品实施特别 审批程序，开辟绿色通道，威高血净中性腹膜透析液等创新产品加速获批，填补了国内空白。 目前，威高血净构建起从透析器、透析机到腹膜透析液的全链条覆盖，成为国内血液净化领域产品线最 丰富的企业，通过技术协同与规模效应形成难以复制的综合竞争优势。 当前，依托医疗器械产业集群政策的配套支持，威高血净在威海、成都、江西等地建立生产基地，形成 全国性产能网络。此外，"十四五"期间的政策支持，也助力威高血净市场开拓，公司市场份额进一步扩 大。 "'十四五'时期是威高血净（603014）实现跨越式发展的黄金期，这一阶段公司完成了国产替代突破、 全产业链构建与资本市场登陆的关键布局。"威高血净向证券时报记者表示。 借助资本市场改革机遇，威高血净于2025年5 ...

"公司坚守'共享发展成果'的理念，上市即实施现金分红，累计派发现金红利6582.31万元（含税），其 中2025年中期分红占同期净利润的29.89%。"威高血净表示。 未来，威高血净将聚焦"创新驱动、全球化布局、产业链延伸"三大方向，持续加大研发投入，推动核心 技术突破与产品迭代升级。同时，重点深耕东南亚、南美、东欧、北非等潜力市场，提升境外市场渗透 率。此外，还将推进收并购布局，拓宽业务发展边界，把握相关赛道进口替代机遇，通过内生与外延结 合实现高质量发展。 （文章来源：证券时报） 作为血透耗材领域国产替代的标杆企业，威高血净紧抓医疗器械产业高质量发展与国产替代加速的政策 机遇，实现了血透耗材市占率领先。"'十四五'时期的政策赋能为威高血净发展提供了关键支撑。"威高 血净介绍，在此时期，国家将血液净化关键技术列为重点攻关方向，设立专项研发资金，公司突破了中 空纤维膜等"卡脖子"技术，21年磨一剑完成"膜法革命"。与此同时，国家对医疗器械创新产品实施特别 审批程序，开辟绿色通道，威高血净中性腹膜透析液等创新产品加速获批，填补了国内空白。 "'十四五'时期是威高血净实现跨越式发展的黄金期，这一阶段公司完成了国产 ...

Group 1 - The core point of the announcement is that Shandong Weigao Blood Purification Products Co., Ltd. has approved a capital increase in its joint venture, Weigao Taiermao (Weihai) Medical Products Co., Ltd., to support the development of peritoneal dialysis fluid business [3][9][14] - The board meeting was held on November 20, 2025, with all nine directors present, and the decision-making process complied with relevant laws and regulations [2][5][16] - The company plans to invest 72.5 million RMB in the joint venture, increasing its registered capital from 160 million RMB to 305 million RMB, while maintaining a 50% ownership stake [8][9][14] Group 2 - The capital increase is part of the company's strategic planning and aims to meet the needs of its peritoneal dialysis fluid business [8][14] - The transaction does not constitute a major asset restructuring and has been approved by the independent directors and the board of directors [9][15][17] - The joint venture's ownership structure remains unchanged, with both the company and Taiermao China holding 50% each [10][14]

Core Points - Weigao Blood Purification announced on November 20 that it has approved a proposal for proportional capital increase in its joint venture with Tailormade (China) Investment Co., Ltd. [1] - The company plans to increase its investment by 72.5 million RMB in Weigao Tailormade (Weihai) Medical Products Co., Ltd. [1] - This capital increase does not require approval from the company's shareholders' meeting. [1]

Group 1 - The core point of the article is that Weigao Blood Products (SH 603014) held its 18th meeting of the second board of directors on November 20, 2025, to review proposals including capital increase in joint ventures and related transactions [1] - For the first half of 2025, Weigao Blood Products reported that its revenue composition was as follows: consumables accounted for 77.55%, equipment accounted for 18.25%, other businesses accounted for 2.35%, and other categories accounted for 1.85% [1] - As of the time of reporting, Weigao Blood Products had a market capitalization of 16.8 billion yuan [1]

Core Viewpoint - Weigao Blood Purification (603014.SH) announced a capital increase to support the development of its peritoneal dialysis fluid business, in collaboration with Terumo China [1] Group 1: Capital Increase Details - The company plans to increase its investment by 72.5 million RMB [1] - After the capital increase, the registered capital of Weigao Terumo will rise from 160 million RMB to 305 million RMB [1] - The company's ownership stake in Weigao Terumo will remain unchanged at 50% [1] Group 2: Joint Venture Structure - Weigao Terumo will continue to be a jointly controlled entity between the company and Terumo China [1]

Core Viewpoint - Weigao Blood Purification (603014.SH) announced a capital increase to support the development of its peritoneal dialysis fluid business, in collaboration with Terumo China [1] Group 1: Capital Increase Details - The company plans to increase its investment by 72.5 million RMB [1] - After the capital increase, the registered capital of Weigao Terumo will rise from 160 million RMB to 305 million RMB [1] - The company's ownership stake in Weigao Terumo will remain unchanged at 50% [1] Group 2: Joint Venture Structure - Weigao Terumo will continue to be a jointly controlled entity between the company and Terumo China [1]

华泰联合证券有限责任公司 关于山东威高血液净化制品股份有限公司 对合营企业同比例增资暨关联交易的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐机构"）作为 山东威高血液净化制品股份有限公司（以下简称"威高血净"或"公司"）首次 公开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券 交易所股票上市规则》等有关规定，对公司拟对合营企业同比例增资暨关联交易 事项进行了审慎核查，核查情况如下： 一、增资暨关联交易概述 （一）基本情况 结合公司战略规划，为满足腹膜透析液业务的发展需要，公司与泰尔茂（中 国）投资有限公司（以下简称"泰尔茂中国"）拟对威高泰尔茂（威海）医疗制品 有限公司（以下简称"威高泰尔茂"）进行同比例增资，其中公司拟增资金额为 0.725 亿元人民币。本次增资完成后，威高泰尔茂的注册资本将由 1.6 亿元人民 币增加至 3.05 亿元人民币，公司对威高泰尔茂的持股比例不变，仍为 50%，威 高泰尔茂仍属于公司与泰尔茂中国共同控制的合营企业。 2025 年 11 月 20 日，公司召开第二届董事会第十八次会议审议通过了《关 于对合营企业同比例增资暨关联交易的议案》。根 ...

Group 1 - The core point of the article is that Weigao Blood Purification (603014.SH) announced a capital increase to support the development of its peritoneal dialysis fluid business [1] - The company plans to invest 72.5 million RMB in Weigao Tailmao (Weihai) Medical Products Co., Ltd. as part of this capital increase [1] - The investment is in collaboration with Tailmao (China) Investment Co., Ltd. to meet the strategic planning needs of the company [1]

证券代码：603014 证券简称：威高血净 公告编号：2025-045 山东威高血液净化制品股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 结合公司战略规划，为满足腹膜透析液业务的发展需要，山东威高血液净化 制品股份有限公司（以下简称"公司"、"本公司"或"威高血净"）与泰尔茂（中 国）投资有限公司（以下简称"泰尔茂中国"）拟对威高泰尔茂（威海）医疗制品 有限公司（以下简称"威高泰尔茂"）进行同比例增资，其中公司拟增资金额为 0.725 亿元人民币； 本次交易已经公司 2025 年第七次独立董事专门会议、第二届董事会第十八 次会议审议通过，关联董事已回避表决，无需提交公司股东会审议； 本次交易不构成重大资产重组。 一、增资暨关联交易概述 （一）本次交易基本情况 结合公司战略规划，为满足腹膜透析液业务的发展需要，公司与泰尔茂中国拟 对威高泰尔茂进行同比例增资，其中公司拟增资金额为 0.725 亿元人民币。本次增资 完成后，威高泰尔茂的注册资本将由 1.6 亿元人民币增加至 3.05 亿元人民币，公司 ...